Aspirin may decrease the risk for developing high-grade prostate cancer
the ONA take:
According to new findings presented at the 13th Annual American Association for Cancer Research International Conference on Frontiers in Cancer Prevention Research in New Orleans, Louisiana, the use of aspirin and other other non-steroidal anti-inflammatory drugs (NSAIDs) were associated with a decreased risk for developing an aggressive form of prostate cancer in patients who had a negative biopsy despite an increased prostate specific antigen (PSA).
The researchers used patients from the REDUCE trial, which studied if dutasteride, a 5-alpha reductase inhibitor, lowers the risk for developing prostate cancer.
Of the 6,390 participants with a PSA between 2.5 ng/mL and 10 ng/mL and a negative biopsy prior to the study, 50% were aspirin/NSAID nonusers, 21% were aspirin users, 18% were NSAID users, and 11% were users of both drugs. They found that aspirin and/or NSAID use decreased the risk for developing prostate cancer by 14%, and after adjusting for confounding factors, 13%.
Furthermore, they found that aspirin and/or NSAID use lowered the risk of high-grade disease by 17%. No link was observed with low-grade prostate cancer. Results were similar among patients from different continents.
Aspirin and other other NSAIDs were associated with a decreased risk for aggressive prostate cancer.
- Prehabilitation Program Improves Preoperative Fitness in Patients With Colorectal Cancer
- Acupuncture Improves Postoperative Symptoms in Women Undergoing Surgery for Breast Cancer
- Combination of Gemcitabine and New CHK1 Inhibitor Is Effective in Soft Tissue Sarcomas
- Alcohol Consumption, Particularly White Wine, Associated With Increased Risk of Melanoma
- In HER2+ Breast Cancer, Higher TIL Levels Associated With Improved OS
- Exercise is as Effective in Treating Metastatic Prostate Cancer as Medication
- Walnut Consumption Changes Gut Microbiome, Decreases Growth of Colon Cancer in Mice
- Vaccine Enters Phase I Study for Safety and Effectiveness in Multiple Myeloma
- Timing Chemotherapy Administration to Circadian Rhythm Improves Drug Effectiveness
- New Therapy Blocks Breast Cancer Cells From Entering and Hiding in Bone Marrow to Form Latent Metastases
- Costs, Complications Higher for Women Who Undergo Second Surgery After BCS
- Omitting RT in Certain Older Women With Early Breast Cancer is Safe
- Fluorescent Nanoparticles Represent Novel Detection Method of HER2 Expression
- Assessment of Stromal Features in DCIS Requires Robustness
- Profile of Tivantinib and its Potential in the Treatment of Hepatocellular Carcinoma: the evidence to date
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|